R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial

NCT01133158 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2018-11-01

Study results available
· View outcomes & findings →

Summary

Assess the combination of efficacy of the combination of rituximab, bendamustine, mitoxantrone, dexamethasone in the treatment of patients with Follicular Lymphoma.

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

DRUG

Rituximab, Bendamustine, Mitoxantrone, Dexamethasone

Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv Dexamethasone 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv

Sponsors & Collaborators

  • Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

    lead OTHER

Principal Investigators

  • Francisco Javier Peñalver Párraga, MD · Hospital Universitario Fundación Alcorcón

  • Javier De la Serna Torroba, MD · Hospital 12 de Octubre

  • Francisca Oña Compan, MD · Hospital de Getafe.

  • Patricia Font López, MD · Gregorio Marañón Hospital

  • Secundino Ferrer Bordas, MD · Hospital Dr. Peset

  • José Ramón Mayans Ferrer, MD · Hospital Arnau de Vilanova

  • Eulogio Conde García, MD · Hospital Marqués de Valdecilla

  • José Antonio Márquez Navarro, MD · Hospital de Basurto

  • Ernesto Pérez Persona, MD · Hospital Txagorritxu

  • Garazi Letamendi Madariaga, MD · Hospital de Galdakao

  • Pilar Giraldo Castellanos, MD · Hospital Miguel Servet

  • Luis Palomera Bernal, MD · Hospital Clínico de Zaragoza

  • Andrés López Hernández, MD · Hospital Vall d´Hebron

  • Blanca Sánchez González, MD · Hospital del Mar

  • José Luis Sánchez-Majado, MD · Hospital San Juan de Alicante

  • Antonio Gutiérrez García, MD · Hospital Son Espases

  • Francisco Javier Capote Huelva, MD · Hospital Universitario Puerta del Mar

  • Fátima de la Cruz, MD · Hospital Virgen del Rocío

  • Mª José Ramírez, MD · Hospital de Jerez

  • Fernando Carnicero González, MD · Hospital San Pedro de Alcantara

  • Mª José Rodríguez Salazar, MD · Hospital Universitario de Canarias

  • Miguel Ángel Canales Albendea, MD · Hospital La Paz

  • José Antonio García Marco, MD · Hospital Puerta de Hierro

  • Carlos Montalbán Sanz, MD · Hospital Universitario Ramon y Cajal

  • Rosalía Riaza Grau, MD · Hospital Severo Ochoa

  • Mª Dolores Caballero Barrigón, MD · Hospital de Salamanca

  • Mª Jesús Peñarrubia Ponce, MD · Hospital Río Hortega

  • José Antonio Queizán, MD · Hospital de Segovia

  • Roberto Hernández Martín, MD · Hospital Virgen de la Concha

  • Mª José Terol Castera, MD · Hospital Clínico de Valencia

  • Félix Carbonell, MD · Hospital General Universitario de Valencia

  • María Rosario Varela Gómez, MD · Complejo Hospitalario A Coruña

  • José Luis Bello López, MD · C. H. U. Santiago

  • Carlos Panizo, MD · Clínica Universitaria de Navarra

  • Juan Manuel Sancho Cia, MD · Germans Trias i Pujol Hospital

  • Armando López Guillermo, MD · Hospital Clínic i Provincial

  • Elena Pérez Ceballos, MD · Hospital Morales Meseguer

  • Andrés Sánchez Salinas, MD · Hospital Universitario Virgen de la Arrixaca

  • Mª Soledad Durán Nieto, MD · Hospital de Jaén

  • Manuel Espeso de Haro, MD · Hospital Carlos Haya

  • Joan Bargay Lleonart, MD · Hospital Son Llàtzer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2013-12-31
Completion
2016-07-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01133158 on ClinicalTrials.gov